The identification of PPARs as key regulators of diverse aspects of energy homeostasis has made them attractive pharmacological targets to treat metabolic diseases such as lipid disorders (drugs targeting PPARα or -δ), T2D (drugs targeting PPARγ), and obesity (drugs targeting PPARδ). Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.